Cancer immunotherapy: More is (much) better

Yosef Yarden; Michael Sela

doi:10.1158/1078-0432.CCR-15-0996

Cancer immunotherapy: More is (much) better

Yosef Yarden, Michael Sela

Weizmann Institute of Science

Research output: Contribution to journal › Article › peer-review

Abstract

Although antibodies against EGFR and HER2 are used to treat cancer, only some patients respond and resistance often emerges. Jacobsen and colleagues present in this issue experimental evidence favoring replacement of the currently applied monoclonal antibodies with oligoclonal mixtures of six synergistic antibodies, simultaneously engaging EGFR, HER2, and also HER3.

Original language	English
Pages (from-to)	4030-4032
Number of pages	3
Journal	Clinical Cancer Research
Volume	21
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.CCR-15-0996
State	Published - 15 Sep 2015

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-15-0996

Cite this

@article{872a656bba9047558acbe8da6cecd2bf,

title = "Cancer immunotherapy: More is (much) better",

abstract = "Although antibodies against EGFR and HER2 are used to treat cancer, only some patients respond and resistance often emerges. Jacobsen and colleagues present in this issue experimental evidence favoring replacement of the currently applied monoclonal antibodies with oligoclonal mixtures of six synergistic antibodies, simultaneously engaging EGFR, HER2, and also HER3.",

author = "Yosef Yarden and Michael Sela",

note = "Publisher Copyright: {\textcopyright} 2015 American Association for Cancer Research.",

year = "2015",

month = sep,

day = "15",

doi = "10.1158/1078-0432.CCR-15-0996",

language = "الإنجليزيّة",

volume = "21",

pages = "4030--4032",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

TY - JOUR

T1 - Cancer immunotherapy

T2 - More is (much) better

AU - Yarden, Yosef

AU - Sela, Michael

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Although antibodies against EGFR and HER2 are used to treat cancer, only some patients respond and resistance often emerges. Jacobsen and colleagues present in this issue experimental evidence favoring replacement of the currently applied monoclonal antibodies with oligoclonal mixtures of six synergistic antibodies, simultaneously engaging EGFR, HER2, and also HER3.

AB - Although antibodies against EGFR and HER2 are used to treat cancer, only some patients respond and resistance often emerges. Jacobsen and colleagues present in this issue experimental evidence favoring replacement of the currently applied monoclonal antibodies with oligoclonal mixtures of six synergistic antibodies, simultaneously engaging EGFR, HER2, and also HER3.

UR - http://www.scopus.com/inward/record.url?scp=84942870660&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-0996

DO - 10.1158/1078-0432.CCR-15-0996

M3 - مقالة

SN - 1078-0432

VL - 21

SP - 4030

EP - 4032

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -

Cancer immunotherapy: More is (much) better

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this